Inhibition of anti-tumour reactivity of immune cells in the salivary gland cancer: A proteomic approach
Background: Adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), and oral squamous cell carcinoma (OSCC) respond differently to immunotherapy. Pembrolizumab, an immune checkpoint inhibitor, has been approved by the Food and Drug Administration for the treatment of squamous cell carcinomas...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Elsevier
2024-03-01
|
| سلاسل: | Oral Oncology Reports |
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://www.sciencedirect.com/science/article/pii/S2772906024000062 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|